Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial

Area of Science:

• Hepatology
• Clinical Pharmacology

Background:

• Severe alcoholic hepatitis is a life-threatening liver condition with high mortality.
• Current treatment options, including prednisolone, have limitations and significant side effects.

Purpose of the Study:

• To compare the efficacy of pentoxifylline versus prednisolone in treating severe alcoholic hepatitis.
• To assess the prognostic value of liver function scores in this patient population.

Main Methods:

• A randomized, double-blind, controlled study involving 68 patients with severe alcoholic hepatitis (Maddrey score ≥ 32).
• Patients received either pentoxifylline or prednisolone for 28 days, followed by an open-label phase and a 12-month follow-up.
• Liver function scores, including Maddrey and MELD, were used for assessment.

Main Results:

• Pentoxifylline group showed significantly lower mortality at 3 months (14.71% vs. 35.29%, P=0.04).
• No hepatorenal syndrome occurred in the pentoxifylline group, compared to six cases in the prednisolone group.
• Pentoxifylline treatment resulted in a lower Model for End-Stage Liver Disease (MELD) score at 28 days.

Conclusions:

• Pentoxifylline demonstrates superior efficacy over prednisolone in severe alcoholic hepatitis, evidenced by reduced mortality and fewer complications.
• Pentoxifylline offers an improved risk-benefit profile and renoprotective effects, making it a preferred treatment choice.
• Higher baseline Maddrey scores correlate with increased mortality risk in severe alcoholic hepatitis.